(R)-Elagolix
Based on 1 publication(s) in Google Scholar
Elagolix is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
For research use only. We do not sell to patients.
- Purity: 96.05%
- CAS No.: 834153-87-6
- Formula: C32H30F5N3O5
- Molecular Weight:631.59
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) (R)-Elagolix
More
Biological Activity
|
GnRHR 0.25 nM (IC50) |
NFAT 5.4 nM (IC50) |
Elagolix is a human GnRH receptor (GnRHR) antagonist, with an IC50 of 0.25 nM in kinase assays[1].
Elagolix also shows NFAT inhibitory effects, with an IC50 of 5.4 nM, and effectively blocks Ca2+ flux, with an IC50 of 0.86 nM[1].
Elagolix is a human GnRH receptor (GnRHR) antagonist, with a Ki value of 3.7 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Main pharmacokinetic parameters after taking a single oral dose of elagolix to rats[3]
| Route | Dose (mg/kg) | AUC0→t (ng•h/mL) | AUC0→∞ (ng•h/mL) | t1/2 (h) | Tmax (h) | Cmax (ng/mL) |
| Oral | 15 | 5212 | 5301 | 6.56 | 1.50 | 1515 |